Loading...
Efficacy and safety of necitumumab continuation therapy in the Phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer.
Ciuleanu, T Socinski, M Obasaju, C Luft, A Szczesna, A Szafrański, W Ramlau, R Bálint, B Molinier, O Depenbrock, H
Ciuleanu, T
Socinski, M
Obasaju, C
Luft, A
Szczesna, A
Szafrański, W
Ramlau, R
Bálint, B
Molinier, O
Depenbrock, H
Citations
Altmetric:
Abstract
In a retrospective analysis of the SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) study, we investigated the efficacy and safety of single-agent necitumumab continuation therapy in patients with stage IV squamous non-small-cell lung cancer and in a subpopulation of patients with epidermal growth factor receptor (EGFR)-expressing tumors.
Description
Date
2017-10-13
Publisher
Collections
Keywords
Type
Article
Citation
Efficacy and safety of necitumumab continuation therapy in the Phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer 2017, Clin Lung Cancer